311 related articles for article (PubMed ID: 25316501)
1. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G
Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440
[TBL] [Abstract][Full Text] [Related]
3. MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET.
Duan L; Hao X; Liu Z; Zhang Y; Zhang G
FEBS Lett; 2014 May; 588(9):1644-51. PubMed ID: 24631532
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
5. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
6. PDCD4 expression in thyroid neoplasia.
Pennelli G; Fassan M; Mian C; Pizzi M; Balistreri M; Barollo S; Galuppini F; Guzzardo V; Pelizzo M; Rugge M
Virchows Arch; 2013 Jan; 462(1):95-100. PubMed ID: 23212265
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis.
Fassan M; Realdon S; Pizzi M; Balistreri M; Battaglia G; Zaninotto G; Ancona E; Rugge M
Dis Esophagus; 2012 Apr; 25(3):263-8. PubMed ID: 21883657
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
[TBL] [Abstract][Full Text] [Related]
11. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
14. Nodal metastasis microRNA expression correlates with the primary tumour in MTC.
Gundara JS; Zhao JT; Gill AJ; Clifton-Bligh R; Robinson BG; Delbridge L; Sidhu SB
ANZ J Surg; 2014 Apr; 84(4):235-9. PubMed ID: 23072640
[TBL] [Abstract][Full Text] [Related]
15. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
[TBL] [Abstract][Full Text] [Related]
16. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
17. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
[TBL] [Abstract][Full Text] [Related]
18. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4.
Wei C; Song H; Sun X; Li D; Song J; Hua K; Fang L
Oncol Rep; 2015 Jul; 34(1):211-20. PubMed ID: 26063221
[TBL] [Abstract][Full Text] [Related]
19. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma.
Fischer N; Göke F; Splittstösser V; Lankat-Buttgereit B; Müller SC; Ellinger J
Biochem Biophys Res Commun; 2012 Jan; 417(1):29-34. PubMed ID: 22133680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]